These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 28239479)

  • 1. The changing landscape of expanded access to investigational drugs for patients with unmet medical needs: ethical implications.
    Bunnik EM; Aarts N; van de Vathorst S
    J Pharm Policy Pract; 2017; 10():10. PubMed ID: 28239479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What do patients with unmet medical needs want? A qualitative study of patients' views and experiences with expanded access to unapproved, investigational treatments in the Netherlands.
    Bunnik EM; Aarts N
    BMC Med Ethics; 2019 Nov; 20(1):80. PubMed ID: 31706313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Little to lose and no other options: Ethical issues in efforts to facilitate expanded access to investigational drugs.
    Bunnik EM; Aarts N; van de Vathorst S
    Health Policy; 2018 Sep; 122(9):977-983. PubMed ID: 29935731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Before It's Too Late: Multistakeholder Perspectives on Compassionate Access to Investigational Drugs for Pediatric Patients With Cancer.
    Gerasimov E; Donoghue M; Bilenker J; Watt T; Goodman N; Laetsch TW
    Am Soc Clin Oncol Educ Book; 2020 May; 40():1-10. PubMed ID: 32412804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Role of Physicians in Expanded Access to Investigational Drugs: A Mixed-Methods Study of Physicians' Views and Experiences in The Netherlands.
    Bunnik EM; Aarts N
    J Bioeth Inq; 2021 Jul; 18(2):319-334. PubMed ID: 33590374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expanded access to investigational drugs: balancing patient safety with potential therapeutic benefits.
    Fountzilas E; Said R; Tsimberidou AM
    Expert Opin Investig Drugs; 2018 Feb; 27(2):155-162. PubMed ID: 29353505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Availability of Investigational Medicines Through the US Food and Drug Administration's Expanded Access and Compassionate Use Programs.
    Puthumana J; Miller JE; Kim J; Ross JS
    JAMA Netw Open; 2018 Jun; 1(2):e180283. PubMed ID: 30646072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overview of FDA's Expanded Access Program for Investigational Drugs.
    Jarow JP; Lurie P; Ikenberry SC; Lemery S
    Ther Innov Regul Sci; 2017 Mar; 51(2):177-179. PubMed ID: 28553565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expanded access to investigational drugs in psychiatry: A systematic review.
    Vermeulen SF; Polak TB; Bunnik EM
    Psychiatry Res; 2023 Nov; 329():115554. PubMed ID: 37890403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ensuring Justice in Access to Investigational Neurological Drugs.
    Kearns L; Bateman-House A; Caplan A
    Semin Neurol; 2018 Oct; 38(5):583-588. PubMed ID: 30321898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Qualitative Interview Study on Expanded Access Clinical Trials for Compassionate Use in Japan.
    Hayashi H; Nogita T; Maeda H
    Patient Prefer Adherence; 2024; 18():1471-1479. PubMed ID: 39011090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. American Society of Clinical Oncology policy statement: oversight of clinical research.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2377-86. PubMed ID: 12721281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fair, just and compassionate: A pilot for making allocation decisions for patients requesting experimental drugs outside of clinical trials.
    Caplan AL; Teagarden JR; Kearns L; Bateman-House AS; Mitchell E; Arawi T; Upshur R; Singh I; Rozynska J; Cwik V; Gardner SL
    J Med Ethics; 2018 Nov; 44(11):761-767. PubMed ID: 29982174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Assessment of Non-trial Access to Investigational Medical Products in the U.S. and Japan.
    Nakada H; Folkers KM; Takashima K
    Ther Innov Regul Sci; 2021 Mar; 55(2):401-407. PubMed ID: 33098080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Should patients in need be given access to experimental drugs?
    Caplan AL; Bateman-House A
    Expert Opin Pharmacother; 2015 Jun; 16(9):1275-9. PubMed ID: 26001178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The 'false hope' argument in discussions on expanded access to investigational drugs: a critical assessment.
    Hordijk M; Vermeulen SF; Bunnik EM
    Med Health Care Philos; 2022 Dec; 25(4):693-701. PubMed ID: 35951276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
    Rossen BR
    Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ethics framework for treatment use of investigational drugs.
    Borysowski J; Górski A
    BMC Med Ethics; 2020 Nov; 21(1):116. PubMed ID: 33208140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Compassionate use of unauthorized drugs: Legal regulations and ethical challenges.
    Borysowski J; Górski A
    Eur J Intern Med; 2019 Jul; 65():12-16. PubMed ID: 31036436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Taking AIM at serious illness: implementing an access to investigational medicines expanded access program.
    Joly MM; Edwards TL; Jerome RN; Mainor A; Bernard GR; Pulley JM
    Front Med (Lausanne); 2023; 10():1287449. PubMed ID: 37877021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.